The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial
ABSTRACT: The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and prov...
- Autores:
-
Rios Romenets, Silvia
Giraldo Chica, Margarita María
López, H.
Piedrahita, F.
Ramos, Claudia Patricia
Acosta Baena, Natalia
Muñoz, C.
Ospina, P.
Tobón Quintero, Carlos Andrés
Cho, William
Ward, M.
Langbaum, Jessica
Tariot, Pierre
Reiman, Eric M.
Lopera Restrepo, Francisco Javier
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2018
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/23012
- Acceso en línea:
- http://hdl.handle.net/10495/23012
- Palabra clave:
- Enfermedad de Alzheimer
Alzheimer Disease
Prevención de Enfermedades
Disease Prevention
Registros
Records
Autosomal dominant Alzheimer’s disease
Alzheimer’s prevention initiative
Registry
Pre- screening
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
id |
UDEA2_d5c5c85cb6d1d6062818fc98c288adf0 |
---|---|
oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/23012 |
network_acronym_str |
UDEA2 |
network_name_str |
Repositorio UdeA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
title |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
spellingShingle |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial Enfermedad de Alzheimer Alzheimer Disease Prevención de Enfermedades Disease Prevention Registros Records Autosomal dominant Alzheimer’s disease Alzheimer’s prevention initiative Registry Pre- screening |
title_short |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
title_full |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
title_fullStr |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
title_full_unstemmed |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
title_sort |
The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease Trial |
dc.creator.fl_str_mv |
Rios Romenets, Silvia Giraldo Chica, Margarita María López, H. Piedrahita, F. Ramos, Claudia Patricia Acosta Baena, Natalia Muñoz, C. Ospina, P. Tobón Quintero, Carlos Andrés Cho, William Ward, M. Langbaum, Jessica Tariot, Pierre Reiman, Eric M. Lopera Restrepo, Francisco Javier |
dc.contributor.author.none.fl_str_mv |
Rios Romenets, Silvia Giraldo Chica, Margarita María López, H. Piedrahita, F. Ramos, Claudia Patricia Acosta Baena, Natalia Muñoz, C. Ospina, P. Tobón Quintero, Carlos Andrés Cho, William Ward, M. Langbaum, Jessica Tariot, Pierre Reiman, Eric M. Lopera Restrepo, Francisco Javier |
dc.subject.decs.none.fl_str_mv |
Enfermedad de Alzheimer Alzheimer Disease Prevención de Enfermedades Disease Prevention Registros Records |
topic |
Enfermedad de Alzheimer Alzheimer Disease Prevención de Enfermedades Disease Prevention Registros Records Autosomal dominant Alzheimer’s disease Alzheimer’s prevention initiative Registry Pre- screening |
dc.subject.proposal.spa.fl_str_mv |
Autosomal dominant Alzheimer’s disease Alzheimer’s prevention initiative Registry Pre- screening |
description |
ABSTRACT: The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds. The pre-screening failure rate was 48.2%: the primary reason was expected inability to comply with the protocol, chiefly due to work requirements. More carriers compared to non-carriers, and more males compared to females, failed pre-screening. Carriers with illiteracy or learning/comprehension difficulties failed pre-screening more than non-carriers. With the Colombian API Registry and our prescreening efforts, we randomized 169 30-60 year-old cognitively unimpaired carriers and 83 non-carriers who agreed to participate in the trial for at least 60 months. Our findings suggest multiple benefits of implementing a pre-screening process for enrolling prevention trials in ADAD. |
publishDate |
2018 |
dc.date.issued.none.fl_str_mv |
2018 |
dc.date.accessioned.none.fl_str_mv |
2021-10-08T02:58:35Z |
dc.date.available.none.fl_str_mv |
2021-10-08T02:58:35Z |
dc.type.spa.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.hasversion.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
dc.type.local.spa.fl_str_mv |
Artículo de investigación |
format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
status_str |
publishedVersion |
dc.identifier.issn.none.fl_str_mv |
2090-8024 |
dc.identifier.uri.none.fl_str_mv |
http://hdl.handle.net/10495/23012 |
dc.identifier.doi.none.fl_str_mv |
10.14283/jpad.2017.44. |
dc.identifier.eissn.none.fl_str_mv |
2090-0252 |
identifier_str_mv |
2090-8024 10.14283/jpad.2017.44. 2090-0252 |
url |
http://hdl.handle.net/10495/23012 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
Int. J. Alzheimers. Dis. |
dc.rights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ |
dc.rights.accessrights.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.creativecommons.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ http://purl.org/coar/access_right/c_abf2 https://creativecommons.org/licenses/by/4.0/ |
dc.format.extent.spa.fl_str_mv |
11 |
dc.format.mimetype.spa.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
Hindawi |
dc.publisher.group.spa.fl_str_mv |
Grupo Neuropsicología y Conducta |
dc.publisher.place.spa.fl_str_mv |
Nueva York, Estados Unidos |
institution |
Universidad de Antioquia |
bitstream.url.fl_str_mv |
http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/1/GiraldoM_2018_ValuePre-ScreeningAlzheimers.pdf http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/3/license.txt http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/2/license_rdf |
bitstream.checksum.fl_str_mv |
ed2439ec1cb6aa9088cacae7f0932998 8a4605be74aa9ea9d79846c1fba20a33 1646d1f6b96dbbbc38035efc9239ac9c |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio Institucional Universidad de Antioquia |
repository.mail.fl_str_mv |
andres.perez@udea.edu.co |
_version_ |
1812173078246981632 |
spelling |
Rios Romenets, SilviaGiraldo Chica, Margarita MaríaLópez, H.Piedrahita, F.Ramos, Claudia PatriciaAcosta Baena, NataliaMuñoz, C.Ospina, P.Tobón Quintero, Carlos AndrésCho, WilliamWard, M.Langbaum, JessicaTariot, PierreReiman, Eric M.Lopera Restrepo, Francisco Javier2021-10-08T02:58:35Z2021-10-08T02:58:35Z20182090-8024http://hdl.handle.net/10495/2301210.14283/jpad.2017.44.2090-0252ABSTRACT: The Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease (ADAD) trial evaluates the anti-amyloid-β antibody crenezumab in cognitively unimpaired persons who, based on genetic background and age, are at high imminent risk of clinical progression, and provides a powerful test of the amyloid hypothesis. The Neurosciences Group of Antioquia implemented a pre-screening process with the goals of decreasing screen failures and identifying participants most likely to adhere to trial requirements of the API ADAD trial in cognitively unimpaired members of Presenilin1 E280A mutation kindreds. The pre-screening failure rate was 48.2%: the primary reason was expected inability to comply with the protocol, chiefly due to work requirements. More carriers compared to non-carriers, and more males compared to females, failed pre-screening. Carriers with illiteracy or learning/comprehension difficulties failed pre-screening more than non-carriers. With the Colombian API Registry and our prescreening efforts, we randomized 169 30-60 year-old cognitively unimpaired carriers and 83 non-carriers who agreed to participate in the trial for at least 60 months. Our findings suggest multiple benefits of implementing a pre-screening process for enrolling prevention trials in ADAD.COL000755111application/pdfengHindawiGrupo Neuropsicología y ConductaNueva York, Estados Unidosinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARTArtículo de investigaciónhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/2.5/co/http://purl.org/coar/access_right/c_abf2https://creativecommons.org/licenses/by/4.0/The Value of Pre-Screening in the Alzheimer's Prevention Initiative (API) Autosomal Dominant Alzheimer's Disease TrialEnfermedad de AlzheimerAlzheimer DiseasePrevención de EnfermedadesDisease PreventionRegistrosRecordsAutosomal dominant Alzheimer’s diseaseAlzheimer’s prevention initiativeRegistryPre- screeningInt. J. Alzheimers. Dis.International Journal of Alzheimer's Disease495451ORIGINALGiraldoM_2018_ValuePre-ScreeningAlzheimers.pdfGiraldoM_2018_ValuePre-ScreeningAlzheimers.pdfArtículo de investigaciónapplication/pdf324897http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/1/GiraldoM_2018_ValuePre-ScreeningAlzheimers.pdfed2439ec1cb6aa9088cacae7f0932998MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-81748http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/3/license.txt8a4605be74aa9ea9d79846c1fba20a33MD53CC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927http://bibliotecadigital.udea.edu.co/bitstream/10495/23012/2/license_rdf1646d1f6b96dbbbc38035efc9239ac9cMD5210495/23012oai:bibliotecadigital.udea.edu.co:10495/230122021-10-07 21:58:35.633Repositorio Institucional Universidad de Antioquiaandres.perez@udea.edu.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 |